



## BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022

April 26, 2022

**Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE)** – [BioNTech SE](#) (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9<sup>th</sup>, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.

The slide presentation and audio of the webcast will be available via this [link](#).

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

United States international:	+1 646 741 3167
United States domestic (toll-free):	+1 877 870 9135
Germany:	+49 (0) 692 2222 625
Conference ID:	3698083

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at <https://biontech.de/>. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

### About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### BioNTech Contacts

#### Investor Relations

Sylke Maas, Ph.D.  
+49 (0)6131 9084 1074  
[investors@biontech.de](mailto:investors@biontech.de)

#### Media Relations

Jasmina Alatovic  
+49 (0)6131 9084 1513  
[Media@biontech.de](mailto:Media@biontech.de)